Jinzhou Jiutai Pharmaceutical Co., Ltd. is a comprehensive pharmaceutical enterprise with a manufacturing history spanning over 70 years. Formerly known as Jinzhou No.1 Pharmaceutical Factory, it was founded in 1951 and restructured into Jinzhou Jiutai Pharmaceutical Co., Ltd. in 1998. The company has been honored with numerous awards, including Provincial Advanced Enterprise, Provincial Civilized Unit, Provincial Technology Leading Enterprise, and Provincial Customer Satisfaction Enterprise.

The company occupies an area of 58,000 square meters, with a registered capital of 40.46 million RMB, and currently employs 1,250 staff members, including 310 engineering and technical personnel. It comprises five production workshops, one R&D center, and one wholly-controlled pharmaceutical trading company. The company produces nearly 100 pharmaceutical varieties. As a domestic manufacturer of the API "Chlorhexidine," the company has developed a comprehensive series of suppository products derived from this ingredient, which are distributed across the country. The solid oral dosage product line features two major series: antipyretic-analgesics and gastrointestinal drugs. The lyophilized powder for injection, "Pantoprazole Sodium for Injection," is a nationally classified Category IV new drug, demonstrating significant efficacy in treating peptic ulcers. The company's gynecological products are produced at a site designated by the former State Pharmaceutical Administration of China as a "Gynecological Drug Production Base." The company maintains a rational product portfolio, robust economic performance, advanced production technology, mature process routes, a complete quality monitoring system, and consistently stable and reliable product quality.

Jiutai Pharmaceutical is a provincial-level Enterprise Technology R&D Center. Over the years, we have successfully developed a range of APIs including Chlorhexidine, Malotilate, Omeprazole Sodium, Pantoprazole Sodium, Betahistine Hydrochloride, Ethylenediamine Diaceturate, and Polyhexamethylene Biguanide Hydrochloride (PHMB), as well as over a dozen finished formulations such as Sanwei Zhichuang Suppositories, Chlorhexidine Suppositories, Metronidazole and Furazolidone Suppositories (Jiutai Kunbao), and Azithromycin Fumarate Capsules. Among these, six new drugs have filled domestic market gaps. This has established four major product series: Chlorhexidine APIs, gynecological suppositories, anti-ulcer drugs, and antipyretic-analgesics.

In recent years, in line with the spirit of deepening state-owned enterprise reforms, Jiutai Pharmaceutical has vigorously promoted innovation in mechanisms, management, and technology, with innovation driving all aspects of our operations. In July 2011, the company underwent an asset restructuring, further optimizing the structure of its various resource elements, accelerating innovation, fully leveraging the potential of the enterprise and its employees, and enhancing production efficiency and competitiveness to ensure sustainable development. To elevate production technology and enhance new product development, the company has recruited outstanding pharmaceutical talents from institutions such as China Pharmaceutical University, Shenyang Pharmaceutical University, and Jiamusi Medical University, and has introduced advanced production equipment from Japan, the UK, Italy, and other countries.

In its business operations, the company adheres to the principle of "Customer First" and takes "Sincerity, Friendliness, Mutual Benefit, and Win-Win" as the starting point for cooperation, honoring contracts and maintaining credibility. We possess a skilled sales force and a stable sales network. Our products are sold nationwide, with a portion exported to Europe and America.

Jinzhou Jiutai Pharmaceutical Co., Ltd. sincerely invites colleagues from the pharmaceutical industry to join us in cooperation!